Biogen (BIIB) : Biogen (BIIB) had a healthy money flow of $4.76 million into the stock during the Tuesdays trading session. The value of bullish trades on upticks was $32.12 million, whereas, investors only sold shares worth $27.36 million on downticks. The stock closed the day with an up-down ratio of 1.17.The money flow in the block trades to the tune of $3.23 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $3.23 million worth of transactions were on upticks. Biogen (BIIB) stock slid $0.15 intraday and traded at 252.4, a change of -0.06% over previous days close. However, for the week, the company shares are 0.44% compared to previous weeks close.
The company Insiders own 0.32% of Biogen shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -9.32% . Institutional Investors own 92.8% of Biogen shares. During last six month period, the net percent change held by insiders has seen a change of -7.26%. In an insider trading activity, The Securities and Exchange Commission has divulged that Koppel Adam, officer (EVP, Strategy and Bus. Dev.) of Biogen Inc., had unloaded 555 shares at an average price of $290 in a transaction dated on June 6, 2016. The total value of the transaction was worth $160,950.
Shares of Biogen Inc. rose by 4.68% in the last five trading days and 2.94% for the last 4 weeks. Biogen Inc. has dropped 5.32% during the last 3-month period . Year-to-Date the stock performance stands at -17.3%.
Biogen (NASDAQ:BIIB): stock turned positive on Tuesday. Though the stock opened at $253.78, the bulls momentum made the stock top out at $254.85 level for the day. The stock recorded a low of $251.29 and closed the trading day at $253.36, in the green by 0.32%. The total traded volume for the day was 1,175,107. The stock had closed at $252.54 in the previous days trading.
Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Companys marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.